Squamous cell carcinoma
Drug research and approvals for squamous cell carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 858 studies of squamous cell carcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 77 drug trials for it since 2013, FDA has 9 approved and 8 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 858
- Trials authorized in Canada: 77
- FDA orphan approvals: 9
- EU medicines: 4
Recruiting Now
Newest start dates first, of 858 recruiting on ClinicalTrials.gov ↗- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous…NCT07156227 · Phase 1 · National Cancer Institute (NCI) · starts Feb 13, 2027
- Intralesional Chemotherapy (IC): Cisplatin + EpinephrineNCT07392580 · Phase 2 · University of Miami · starts Dec 1, 2026
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and…NCT07667400 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Nov 19, 2026
- A Study of Retifanlimab After Chemoradiation in People With Anal CancerNCT07927998 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Nov 4, 2026
- Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab…NCT07783581 · Phase 2 · Mayo Clinic · starts Nov 4, 2026
- Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck CancerNCT07784855 · Not applicable · West Virginia University · starts Nov 1, 2026
- A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid TumorsNCT07887971 · Phase 1 · Aktis Oncology, Inc. · starts Nov 1, 2026
- CCR2 PET Imaging Head and Neck Squamous Cell CarcinomaNCT07659678 · Phase 2 · Washington University School of Medicine · starts Oct 31, 2026
- Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell…NCT07741565 · Early Phase 1 · Vanderbilt-Ingram Cancer Center · starts Oct 30, 2026
- Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant LesionsNCT07631013 · Phase 1 · M.D. Anderson Cancer Center · starts Oct 30, 2026
Trials Authorized in Canada
The 10 newest of 77; search them all in Canada trials| Oct 22, 2026 | A phase 3, randomized, open-label, multicenter trial of amivantamab as sequential therapy following definitive, platinum-based, concurrent chemoradiotherapy,…RYBREVANT (AMIVANTAMAB0 | Johnson & Johnson | Pending |
| Oct 2, 2026 | A phase 2/3 multicenter, randomized, open-label study of asp-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in the…ASP-1929 (CETUXIMAB-IR700) | RAKUTEN MEDICAL, INC. | Pending |
| Jun 26, 2026 | A phase 1/2, open-label trial to evaluate safety, immunogenicity, and anti-tumor activity of vb10.16 in combination with pembrolizumab in patients with…VB10.16 (ABIPAPOGENE SUVAPLASMID) / PEMBROLIZUMAB | NYKODE THERAPEUTICS ASA | Pending |
| Apr 23, 2026 | A phase 1 first-in-human, open-label study evaluating the safety, pharmacokinetics, and efficacy of abbv-711 as a monotherapy or in combination with…ABBV-711 / BUDIGALIMAB (ABBV-181) | AbbVie | Ongoing |
| Dec 19, 2025 | Capecitabine prior to tumor resection in entoncology (capture)CAPECITABINE | RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE | Pending |
| Dec 10, 2025 | Gsk5764227 (anti-b7h3 antibody drug conjugate) monotherapy or in combination with dostarlimab in recurrent/metastatic (r/m) head and neck squamous cell…GSK5764227 / DOSTARLIMAB | UNIVERSITY HEALTH NETWORK | Ongoing |
| Aug 7, 2025 | A randomized, phase 3, open-label study to evaluate pf-08046054 / sgn pdl1v in combination with pembrolizumab vs pembrolizumab monotherapy in adult…PF-08046054 (SGN-PDL1V) / KEYTRUDA | Pfizer | Closed |
| Apr 3, 2025 | Randomized phase III trial of neoadjuvant immunotherapy with response adapted treatment versus standard-of-care treatment for resectable stage iii/iv cutaneous…LIBTAYO [CEMIPLIMAB (REGN2810)] | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Jun 5, 2024 | A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of…MCLA-158 (PETOSEMTAMAB) / KEYTRUDA | MERUS N.V. | Ongoing |
| Apr 19, 2024 | A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator¿s choice monotherapy…MCLA-158 (PETOSEMTAMAB) / ERBITUX (CETUXIMAB) / METHOTREXATE INJECTION USP… | Genmab | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 17| May 15, 2025 | Zynyzin combination with carboplatin and paclitaxel, for the first-line treatment of adult patients with inoperable locally recurrent or… | Incyte Corporation | Approved |
| Mar 3, 2025 | Tevimbrain combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal… | BeOne Medicines USA, Inc. | Approved |
| Mar 13, 2024 | Tevimbraas a single agent, for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior… | BeOne Medicines USA, Inc. | Approved |
| May 27, 2022 | OpdivoIn combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous… | Bristol-Myers Squibb Company | Approved |
| May 27, 2022 | OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with… | Bristol-Myers Squibb Company | Approved |
| Jun 10, 2020 | OpdivoOpdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell… | Bristol-Myers Squibb Company | Approved |
| Jul 30, 2019 | KeytrudaKEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus… | MSD International Business GmbH | Approved |
| Jun 13, 2014 | LYMPHOSEEKGuiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of… | Cardinal Health 414, LLC | Approved |
| Mar 1, 2006 | ErbituxFor use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and… | ImClone Systems Incorporated | Approved |
| Mar 24, 2025 | an anti-CD228 monoclonal antibody conjugated with MMAE…treatment of metastatic (stage IV) lung squamous cell carcinoma | Shandong Boan Biotechnology Co., Ltd. | Designated |
| Jan 7, 2021 | zinflavonoidsTreatment of anatomical sites of squamous cell carcinoma of oral cavity and oropharynx accessible for local and topical administration | Aveta Biomics, Inc. | Designated |
| Sep 4, 2014 | Adenovirus serotype-5 (Ad5) vector that contains a modified…Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) | Etubics Corporation | Designated |
| Jan 12, 2009 | HPV-16 cancer therapeutic trojan peptide vaccineTreatment of HPV-16 expressing head and neck squamous cell carcinoma. | Gliknik, Inc. | Designated |
| May 4, 2007 | leukocyte interleukinNeoadjuvant therapy in patients with squamous cell carcinoma of the head and neck | CEL-SCI Corporation | Designated |
| Jul 7, 2005 | human leukocyte-derived cytokine mixtureNeoadjuvant therapy in patients with squamous cell carcinoma of the head and neck | IRX Therapeutics, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Apr 19, 2024 | Zynyzretifanlimab · orphan | Incyte Biosciences Distribution B.V. | EMA ↗ |
| Sep 15, 2023 | Tevimbratislelizumab | Beone Medicines Ireland Limited | EMA ↗ |
| Jun 28, 2019 | Libtayocemiplimab | Regeneron Ireland Designated Activity Company (DAC) | EMA ↗ |
| Oct 24, 2001 | Foscantemoporfin | Biolitec Pharma Ltd | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA